

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1
-------	---

1

9

3

Complete if Known

Application Number

10/561.396

Filing Date

June 17, 2004

First Named Inventor

Avner YAYON

Group Art Unit

Examiner Name

Attorney Docket Number

YAYON11

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

/Ronald Schwadron/

Date
Considered

09/23/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 501.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of

2

Complete if Known

Application Number	10/561,396
Filing Date	June 17, 2004
First Named Inventor	Avner YAYON
Group Art Unit	
Examiner Name	
Attorney Docket Number	YAYON11

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AC	BAECKLUND, E. et al., "Lymphoma Subtypes in patients with Rheumatoid Arthritis"; Arthritis & Rheumatism; Vol. 48, No. 6, June 2003, pp. 1543-1550	
	AD	SIMON, J.A., "Biologic therapy in rheumatoid arthritis"; Rev Invest Clin; Vol. 53, No. 5, 2001, pp. 452-459	
	AE	NEPOM, G.T. et al., "Therapy of autoimmune diseases: clinical trials and new biologics"; Therapy; clinical trials; 2002, Vol. 14, pp. 812-815	
	AF	SMOLEN, J.S. et al., "Therapeutic Strategies for Rheumatoid Arthritis"; Nature Reviews; Vol. 2, June 2003, pp. 473-488	
	AG	PALEOLOG, E.M., "Angiogenesis in rheumatoid arthritis"; Arthritis Res; 2002, Vol. 4, pp. S81-S90	
	AH	MANABE, N. et al., "Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients"; Rheumatology; 1999, Vol. 38, pp. 714-720	
	AI	PATERSON, J.L. et al., "Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma"; British Journal of Haematology, Vol. 124, pp. 595-603	
	AJ	GRAND, EK et al., "Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD1730074"; Leukemia, 2004, Vol. 18, pp. 962-966	
	AK	GREGERSEN, J.W. et al., "Humanized animal models for autoimmune diseases"; Tissue Antigens, 2004, Vol. 63, pp. 383-394	

Examiner
Signature

/Ronald Schwadron/

Date
Considered

09/23/2008

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.S./